We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for revenues is pegged at $3.24 billion, while the same for earnings is pinned at $0.50 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Factors to Consider
The company reports under four segments — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China.
Growth in Developed Markets, driven by strong new product performance and other generics, is likely to have boosted the top line.
Growth in Europe is anticipated to have been driven by contributions from new products and strong generic portfolios. The thrombosis portfolio and key brands must have also driven growth from this geography. Volume growth in key markets, including Italy and France, and strong generic performance have also likely boosted sales.
However, revenues from North America have likely been under pressure due to inspections in the manufacturing facility in Indore, India, and expected competition in the generic business.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $1.9 billion.
Emerging Markets have likely witnessed growth on the back of the expansion of their cardiovascular portfolio in certain Latin American countries, as well as expansion in key markets such as Turkey, India, Korea, Brazil and emerging Asia, and volume growth in the overall base portfolio. The Zacks Consensus Estimate for revenues from this geography is pegged at $480 million.
Sales in JANZ are likely to have been adversely impacted by government-driven price regulations in Japan and Australia, as well as by a change in Japan's reimbursement for off-patent brands that accelerated generic conversion. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $309 million.
Sales in Greater China might have seen an increase due to continued patient demand for a portfolio of iconic brands addressing chronic diseases that are more and more prevalent in this country’s growing aging population.
The Zacks Consensus Estimate for revenues from this geography is pegged at $553 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business makes up the majority of the company’s portfolio. Brand performance is likely to have benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China.
Operating expenses might have risen during the quarter due to SG&A investments in new product launches and progress in key R&D programs.
VTRS’ Share Price Performance
Viatris’ shares have lost 31.2% in the past year compared with the industry’s decline of 1%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 1.26%. In the last reported quarter, VTRS missed on earnings by 5.26%.
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of +3.31% as the Zacks Consensus Estimate is pegged at 50 cents and the Most Accurate Estimate is pinned at 52 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around.
ANIP beat on earnings in each of the trailing four quarters, delivering an average surprise of 17.32%. ANIP is scheduled to report first-quarter results on May 9.
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) has an Earnings ESP of +0.4% and a Zacks Rank #3 at present.
VRTX beat on earnings in two of the trailing four quarters and missed in the other two, delivering an average surprise of 2.58%. VRTX is scheduled to report first-quarter results on May 5.
Denali Therapeutics (DNLI - Free Report) has an Earnings ESP of +4.87% and a Zacks Rank #3 at present.
DNLI beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 6.51%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris Q1 Earnings Release: What's in Store for the Stock?
Viatris (VTRS - Free Report) , a global healthcare company, is scheduled to report first-quarter 2025 results on May 8, 2025.
The Zacks Consensus Estimate for revenues is pegged at $3.24 billion, while the same for earnings is pinned at $0.50 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Factors to Consider
The company reports under four segments — Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China.
Growth in Developed Markets, driven by strong new product performance and other generics, is likely to have boosted the top line.
Growth in Europe is anticipated to have been driven by contributions from new products and strong generic portfolios. The thrombosis portfolio and key brands must have also driven growth from this geography. Volume growth in key markets, including Italy and France, and strong generic performance have also likely boosted sales.
However, revenues from North America have likely been under pressure due to inspections in the manufacturing facility in Indore, India, and expected competition in the generic business.
The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $1.9 billion.
Emerging Markets have likely witnessed growth on the back of the expansion of their cardiovascular portfolio in certain Latin American countries, as well as expansion in key markets such as Turkey, India, Korea, Brazil and emerging Asia, and volume growth in the overall base portfolio. The Zacks Consensus Estimate for revenues from this geography is pegged at $480 million.
Sales in JANZ are likely to have been adversely impacted by government-driven price regulations in Japan and Australia, as well as by a change in Japan's reimbursement for off-patent brands that accelerated generic conversion. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $309 million.
Sales in Greater China might have seen an increase due to continued patient demand for a portfolio of iconic brands addressing chronic diseases that are more and more prevalent in this country’s growing aging population.
The Zacks Consensus Estimate for revenues from this geography is pegged at $553 million.
Viatris also reports revenues under two divisions (in terms of product category) — brands and generics.
Brand business makes up the majority of the company’s portfolio. Brand performance is likely to have benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China.
Operating expenses might have risen during the quarter due to SG&A investments in new product launches and progress in key R&D programs.
VTRS’ Share Price Performance
Viatris’ shares have lost 31.2% in the past year compared with the industry’s decline of 1%.
Image Source: Zacks Investment Research
VTRS’ Mixed Earnings Surprise History
The company’s earnings beat estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 1.26%. In the last reported quarter, VTRS missed on earnings by 5.26%.
Viatris Inc. Price, Consensus and EPS Surprise
Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote
What Our Model Predicts for Viatris
Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: VTRS has an Earnings ESP of +3.31% as the Zacks Consensus Estimate is pegged at 50 cents and the Most Accurate Estimate is pinned at 52 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around.
ANI Pharmaceutcials, Inc. (ANIP - Free Report) has an Earnings ESP of +0.86% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANIP beat on earnings in each of the trailing four quarters, delivering an average surprise of 17.32%. ANIP is scheduled to report first-quarter results on May 9.
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) has an Earnings ESP of +0.4% and a Zacks Rank #3 at present.
VRTX beat on earnings in two of the trailing four quarters and missed in the other two, delivering an average surprise of 2.58%. VRTX is scheduled to report first-quarter results on May 5.
Denali Therapeutics (DNLI - Free Report) has an Earnings ESP of +4.87% and a Zacks Rank #3 at present.
DNLI beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 6.51%.